Deferoxamine mesilate (DrugBank: Deferoxamine)
3 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 0 |
| 284 | ダイアモンド・ブラックファン貧血 | 0 |
| 286 | 遺伝性鉄芽球性貧血 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-021062-29-GR (EUCTR) | 12/04/2011 | 02/02/2011 | Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION | Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION | transfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overload MedDRA version: 13.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 10027433 - Metabolism and nutrition disorders | Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Trade Name: Desferal Product Name: deferoxamine Product Code: DFO INN or Proposed INN: DEFEROXAMINE MESILATE Trade Name: DESFERAL Product Name: deferoxamine Product Code: DFO INN or Proposed INN: DEFEROXAMINE MESILATE | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 45 | Phase 2 | Greece;Italy;United Kingdom | ||
| 2 | EUCTR2010-021062-29-GB (EUCTR) | 21/12/2010 | 20/10/2010 | Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION | Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION | transfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overload MedDRA version: 14.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 10027433 - Metabolism and nutrition disorders | Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: DEFERASIROX Other descriptive name: Exjade Product Name: deferoxamine Product Code: DFO INN or Proposed INN: DEFEROXAMINE MESILATE Product Name: deferoxamine Product Code: DFO INN or Proposed INN: DEFEROXAMINE MESILATE Trade Name: Exjade Product Name: Exjade Product Code: ICL670 INN or Proposed INN: deferasirox INN or Proposed INN: deferasirox INN or Proposed INN: deferasirox | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 45 | Phase 2 | Greece;Italy;United Kingdom |